Accessibility StatementSkip Navigation NEW YORK, Oct. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. ("Baxter International, Inc." or the "Company") (NYSE: BAX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Baxter International, Inc. investors who were adversely affected by alleged securities fraud between February 23, 2022 and July 30, 2025. Follow the link below to get more information and be contac ...

Core Insights - Baxter International Inc. is a global healthcare company providing essential medical products, including devices, pharmaceuticals, and biotechnology, with a focus on Medical Products and Therapies [1] - The company faces competition from major players like Johnson & Johnson and Medtronic [1] Financial Performance - Baxter reported a third-quarter adjusted EPS of 69 cents, exceeding management's guidance of 58-62 cents and Wall Street's estimate of 60 cents [3] - The company's sales for the third quarter were $2.84 billion, reflecting a 5% year-over-year increase on a reported basis and a 2% increase on an operational basis, closely aligning with the consensus of $2.88 billion [4] - Despite the positive EPS results, Baxter lowered its 2025 guidance, which negatively impacted investor sentiment [3][6] Segment Performance - The Medical Products and Therapies segment reported sales of approximately $1.33 billion, showing a 1% decline on both a reported and operational basis, primarily due to reduced sales in the Infusion Therapies and Technologies division [5][6] - Strong global demand for other products partially offset the decline in the Medical Products and Therapies segment [5] Market Outlook - Stifel Nicolaus set a price target of $22 for Baxter, indicating a potential upside of approximately 14.73% from the current stock price of $19.18 [2] - Despite the optimistic price target, Baxter's stock has experienced a significant drop, reaching a 52-week low [2][6]

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased Baxter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Baxter International, Inc. (NYSE: BAX). Shareholders who purchased shares of BAX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/baxter-international-inc-loss-submission-form-2/?id=174509&from=3 CLASS PERI ...

Baxter International Inc. (NYSE:BAX) stock hit a 52-week low on Thursday, after the company again lowered its 2025 guidance.BAX stock is at key technical levels. See the trading setup hereBaxter reported a third-quarter adjusted EPS of 69 cents, surpassing the management guidance of 58-62 cents and the Wall Street estimate of 60 cents.The medical device maker reported sales of $2.84 billion, up 5% year-over-year on a reported basis and 2% on an operational basis. That's almost in line with the consensus of ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Baxter International, Inc. ("Baxter†or the "Company†) (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, inclusive (the "Class Period†). IF YOU SUFFERED A LOSS ON YOUR BAXTER INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CL. ...

Key Takeaways BAX's Q3 EPS of 69 cents beat estimates by 15%, though revenues of $2.84B missed expectations.BAX's Advanced Surgery sales rose 13%, offsetting softness in Infusion Therapies and IV solutions.BAX cut 2025 EPS view to $2.35-$2.40, prompting a 10.9% pre-market stock decline.Baxter International Inc. (BAX) reported third-quarter 2025 adjusted earnings per share (EPS) of 69 cents, which beat the Zacks Consensus Estimate of 60 cents by 15%. The bottom line declined 14% from the year-ago quarter’s l ...

Baxter International (BAX) reported $2.84 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 5%. EPS of $0.69 for the same period compares to $0.80 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.87 billion, representing a surprise of -1.32%. The company delivered an EPS surprise of +15%, with the consensus EPS estimate being $0.60.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wa ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Baxter between February 23, 2022 and July 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...

Baxter International (NYSE:BAX) Q3 2025 Earnings Call October 30, 2025 08:30 AM ET Company ParticipantsJoanne Wuensch - Managing Director and Head of US Healthcare ResearchJoel Grade - EVP and CFOVijay Kumar - Senior Managing Director of Healthcare Services and Technology Research TeamKevin Moran - VP of Investor RelationsDavid Roman - Managing DirectorAndrew Heider - President and CEOMatt Taylor - Managing DirectorConference Call ParticipantsMatt Mixkit - Equity Research AnalystTravis Steed - Managing Dire ...